Evidence map›Paper›PMID 42835240›Full record

ArticleiScience2026

Decomposition-driven biomarker identification enhances non-invasive early cancer detection.

Weizhong Chen, Ying-Hong An, Rui-Qing Fu, Hai-Xiang Sun, Wen-Jing Zheng, Fang Wang, Hua Chen, Wei Li, Min-Jie Xu, Cheng-Cheng Ma and 3 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weizhong ChenPrecision Medicine Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ying-Hong AnDepartment of Clinical Laboratory, Air Force Medical Center, Air Force Medical University, Beijing 100142, China.
Rui-Qing FuSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Hai-Xiang SunDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China.
Wen-Jing ZhengDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China.
Fang WangDepartment of Gastroenterology and Hepatology, Tianjin Third Central Hospital, 83 Jintang Road, Hedong, Tianjin 300170, China.
Hua ChenSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Wei LiSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Min-Jie XuSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Cheng-Cheng MaSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Zhi-Xi SuSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Rui LiuSinglera Genomics (Shanghai) Ltd., Shanghai 201203, China.
Xin-Rong YangPrecision Medicine Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate marker selection in cell-free DNA (cfDNA) is essential for non-invasive early cancer detection, yet conventional approaches based on bulk tissue data often yield markers with limited efficacy in blood-based assays, due to the sparse and heterogeneous nature of tumor-derived cfDNA released into the bloodstream during early tumorigenesis. Here, we present a component decomposition framework that leverages non-negative matrix factorization (NMF) to resolve distinct methylation components from bulk reduced representation bisulfite sequencing (RRBS) data of five gastrointestinal cancers and their para-carcinoma tissues. This approach demonstrates that cancer-specific signals can be recovered at the component level, enabling the identification of cancer-specific and tissue-of-origin markers with significantly improved performance in cfDNA. Extending this framework to transcriptomic data further validates its utility for cfRNA-based biomarker discovery and molecular subtyping. Together, our framework offers a robust and scalable solution to improve biomarker identification for early cancer detection and patient stratification.

Indexed as

biomarkerdata decompositiondiagnosticsearly cancer detectionmarker selectionTOO marker

Identifiers

PMID42835240
PMCPMC13634983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.